资讯
Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.
Eli Lilly will significantly increase the price of its weight-loss drug Mounjaro in the United Kingdom in a bid to bring down ...
Trump’s push for price cuts and tariffs weighs on ‘obesity franchises’, which have missed out on equity market’s rise ...
Wall Street loves a dominant player, and Eli Lilly (NYSE: LLY) looks unstoppable with its obesity blockbusters printing money ...
The pricing of weight-loss and diabetes drugs like Lilly’s Zepbound and Mounjaro, and Novo’s Wegovy and Ozempic, is a ...
The new price, which also applies to Lilly's type 2 diabetes medicine that has the same name, is effective from September ...
2 天
Pharmaceutical Technology on MSNEli Lilly seeks more GPCR weight loss drugs in $1.3bn research deal
Lilly has been a long-time backer of Superluminal, with the US big pharma company taking part in a $120m Series A round in ...
A legacy ranch in Jackson Hole, WY, has come onto the market, with records showing it is owned by former Eli Lilly exec Dr.
Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly “bribing” providers to prescribe its ...
1 天
Scripps News on MSNEli Lilly's experimental weight loss pill showcases promising weight loss results
Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight, potentially transforming diabetes and obesity treatment.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果